Abstract
Purpose: To evaluate adalimumab as an immunomodulatory treatment for non-infectious ocular inflammatory diseases. Methods: Characteristics of patients treated with adalimumab were abstracted in a standardized chart review. Main outcomes measured were control of inflammation, corticosteroid-sparing effect, and visual acuity. Results: In total, 32 patients with ocular inflammation were treated with adalimumab. The most common ophthalmic diagnoses were anterior uveitis, occurring in 15 patients (47%), and scleritis, occurring in 9 patients (28%). At 6 months of therapy, among 15 eyes with active inflammation, 7 (47%) became completely inactive, and oral prednisone was reduced to ≤10 mg/day in 2 of 4 patients (50%). On average, visual acuity decreased by 0.13 lines during the first 6 months of treatment. Adalimumab was discontinued because of lack of effectiveness in four patients within 6 months. Conclusions: Adalimumab was moderately effective in controlling inflammation in a group of highly pre-treated cases of ocular inflammatory disease.
Original language | English (US) |
---|---|
Pages (from-to) | 405-412 |
Number of pages | 8 |
Journal | Ocular Immunology and Inflammation |
Volume | 25 |
Issue number | 3 |
DOIs | |
State | Published - May 4 2017 |
Keywords
- Adalimumab
- Humira
- TNF-α antibody
- ocular inflammatory disease
- scleritis
- uveitis
ASJC Scopus subject areas
- Immunology and Allergy
- Ophthalmology